Are specialized pro-resolving mediators promising therapeutic agents for severe bronchial asthma?

Affiliations

Editorial

Takeshi Hisada et al. J Thorac Dis. 2017 Nov.

. 2017 Nov;9(11):4266-4269.

doi: 10.21037/jtd.2017.10.116.

¹ Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

1. Ichinose M, Sugiura H, Nagase Het al. Japanese guidelines for adult asthma 2017. Allergol Int 2017;66:163-89. 10.1016/j.alit.2016.12.005 - DOI - PubMed
1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73. 10.1183/09031936.00202013 - DOI - PubMed
1. Chastek B, Korrer S, Nagar SP, et al. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. J Manag Care Spec Pharm 2016;22:848-61. 10.18553/jmcp.2016.22.7.848 - DOI - PMC - PubMed
1. Anderson GP. Endo typing asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-19. 10.1016/S0140-6736(08)61452-X - DOI - PubMed
1. Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med 2017;58:1-11. 10.1016/j.mam.2017.03.001 - DOI - PMC - PubMed